Abstract
Background: OBELICS was a randomized phase 3 trial evaluating the optimization of bevacizumab schedule in the treatment of advanced colorectal cancer, not suitable for curative surgery. The sequential schedule of bevacizumab, given 3 days before chemotherapy, did not improve response rate nor progression-free survival (PFS), while prolonged median overall survival (OS) of about 6 months
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call